These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19030742)

  • 41. Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    Floridia M; Tamburrini E; Anzidei G; Tibaldi C; Guaraldi G; Guerra B; Meloni AM; Vimercati A; Molinari A; Pinnetti C; Dalzero S; Ravizza M;
    AIDS Patient Care STDS; 2009 Mar; 23(3):147-52. PubMed ID: 19866532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small-dense LDL cholesterol/large-buoyant LDL cholesterol ratio as an excellent marker for indicating lipodystrophy in HIV-infected patients.
    Srisawasdi P; Suwalak T; Sukasem C; Chittamma A; Pocathikorn A; Vanavanan S; Puangpetch A; Santon S; Chantratita W; Kiertiburanakul S; Kroll MH
    Am J Clin Pathol; 2013 Oct; 140(4):506-15. PubMed ID: 24045547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    Negredo E; Ribalta J; Paredes R; Ferré R; Sirera G; Ruiz L; Salazar J; Reiss P; Masana L; Clotet B
    AIDS; 2002 Jul; 16(10):1383-9. PubMed ID: 12131215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipodystrophy induced by combination antiretroviral therapy in HIV/AIDS patients: a Belgrade cohort study.
    Dragović G; Danilović D; Dimić A; Jevtović D
    Vojnosanit Pregl; 2014 Aug; 71(8):746-50. PubMed ID: 25181834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study.
    Gelenske T; e Farias FA; de Alencar Ximenes RA; de Melo HR; de Albuquerque Mde F; de Carvalho EH; de Medeiros Barros Z; Diniz GT; Filho Dde B
    Metab Syndr Relat Disord; 2010 Jun; 8(3):271-7. PubMed ID: 20158442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
    Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What should we know about metabolic syndrome and lipodystrophy in AIDS?
    Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
    Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.
    Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Choi JY; Song YG; Lee HC; Kim JM
    Metabolism; 2009 Nov; 58(11):1523-9. PubMed ID: 19501863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of lipodystrophy on quality of life and depression in HIV-infected men on HAART.
    Steel JL; Landsittel D; Calhoun B; Wieand S; Kingsley LA
    AIDS Patient Care STDS; 2006 Aug; 20(8):565-75. PubMed ID: 16893326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].
    Ongolo-Zogo P; Nkodo Mbia N; Mvogo Minkala TL; Biwole Sida M; Kouanfack C; Nko Amvene S
    Bull Soc Pathol Exot; 2012 Dec; 105(5):353-60. PubMed ID: 22886433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
    Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
    Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in Lipid Indices in HIV+ Cases on HAART.
    Ji S; Xu Y; Han D; Peng X; Lu X; Brockmeyer NH; Wu N
    Biomed Res Int; 2019; 2019():2870647. PubMed ID: 30868068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage.
    Bezante GP; Briatore L; Rollando D; Maggi D; Setti M; Ghio M; Agosti S; Murdaca G; Balbi M; Barsotti A; Cordera R
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):277-82. PubMed ID: 19422999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Metabolic alterations in HIV-associated lipodystrophy syndrome].
    Valente AM; Reis AF; Machado DM; Succi RC; Chacra AR
    Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):871-81. PubMed ID: 16544008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.